A Case of Ticlopidine-Induced Cholastatic Jaundice
Published Online: Jul 24, 2015
Abstract
Ticlopidine, a platelet aggregation inhibitor, is widely used in the secondary prevention of stroke and previous manifestation of peripheral arterial occlusive disease, Ticlopidine is also used to prevent myocardial infarction and post-stenting occlusion after intracoronary stent implantation. The exact mechanism of action of ticlopidine is unclear, but likely involves the inhibition of platelet activity by the suppression of adenosine diphosphate-induced patelet aggregation. The most common adverse effects are gastrointestinal problems, skin reactions, and hematologist changes. The adverse hepatic effects are not frequent(4% in different series).
We experienced a case of ticlopidine-induced cholastatic jaundice, and report with review of literatures.
Metrics
QR Code of this Article:
Related Articles
Acute Myocardial Infarction Occurred in Multivessel Disease Including Chronic Total Occlusion
Ewha Med J 2015;38(3):133-137.
The Differences of Left Ventricular Geometry in Acute Myocardial Infarction and the Effects on Short Term Mortality
Ewha Med J 2013;36(1):26-34.
A Clinical Study on Acute Myocardial Infarction: An Analysis for Cause of Death in the Thrombolytic Era
Ewha Med J 1998;21(2):63-72.
Evaluation of Cardiac Troponin T Elevation in Patients with Chronic Renal Failure Undergoing Dialysis
Ewha Med J 2010;33(2):81-87.
Early Result of Off-Pump Coronary Artery Bypass
Ewha Med J 2005;28(1):27-32.
